Company / Capital Expenditures
Coherus Oncology, Inc. Capital Expenditures History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.8M
FY2019
5-year range
$373.0K / $4.6M
FY2015-FY2019
Trend
+130.9%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 6 years, ranging from $373,000 in FY2015 to $5M in FY2017.
Based on SEC 10-K filings.
$2M in FY2019 with a 5-year CAGR of +0.4%.
Declined from $5M to $2M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -13.8%
- 5-Year CAGR
- +0.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.4%, indicating consistent growth.
- In FY2019, capital expenditures increased 130.9% year-over-year.
- Peak capital expenditures was recorded in FY2017.
- Lowest capital expenditures in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $1.8M | +130.9% |
| FY2018 | $789.0K | -82.7% |
| FY2017 | $4.6M | +60.5% |
| FY2016 | $2.8M | +663.8% |
| FY2015 | $373.0K | -79.1% |
| FY2014 | $1.8M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026